CVS - CVS Health Corporation
72.77 -0.92 (-1.25%)
After hours: 7:55PM EDT
| Previous Close | 74.62 |
| Open | 74.30 |
| Bid | 0.00 x 1400 |
| Ask | 73.25 x 1800 |
| Day's Range | 73.31 - 74.60 |
| 52 Week Range | 60.14 - 84.00 |
| Volume | 5,072,582 |
| Avg. Volume | 7,738,659 |
| Market Cap | 75.021B |
| Beta | 0.88 |
| PE Ratio (TTM) | 25.09 |
| EPS (TTM) | 2.94 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | 2.00 (2.71%) |
| Ex-Dividend Date | 2018-07-24 |
| 1y Target Est | 86.10 |
- Thomson Reuters StreetEvents•2 hours ago
Edited Transcript of CVS earnings conference call or presentation 8-Aug-18 12:30pm GMT
Q2 2018 CVS Health Corp Earnings Call
- Zacks•7 hours ago
Pharmacies and Drug Stores Stock Outlook: Prospects Bright
Pharmacies and Drug Stores Stock Outlook: Prospects Bright
- MarketWatch•21 hours ago
Investors have misdiagnosed Amazon’s push into the pharmacy business
Walgreens and other established drug retailers can handle Amazon’s threat, writes Vitaliy Katsenelson.
- Reuters•yesterday
U.S. health secretary says agency can eliminate drug rebates
U.S. Health and Human Services Secretary Alex Azar said it was within his agency's power to eliminate rebates on prescription drug purchases, a key element of the Trump administration's plan to lower prescription medicine costs. Such rebates are negotiated in the United States by pharmacy benefits managers (PBMs) to lower the cost of medicines for their clients, including large employers and health plans that cover tens of millions of Americans. Drugmakers say they are under pressure to provide rebates to the few PBMs that dominate the market, which include CVS , Express Scripts and UnitedHealth's Optum , and that those payers do not pass on enough of those savings to patients - a contention the PBMs dispute.
- MarketWatch•2 days ago
An economist’s change of heart: It’s time to regulate the prescription-drug middlemen
Pharmacy-benefit managers may drive hard bargains with drug manufacturers, but they keep finding ways to boost their bottom line at the expense of employers and patients.
- Zacks•5 days ago
CVS Health's PBM Selling Season Strong, Aetna Deal on Track
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
- InvestorPlace•6 days ago
Why Does Mark Cuban Own Netflix, Amazon Shares When He’s Worried About the Market?
Billionaire entrepreneur and investor Mark Cuban appeared on CNBC recently and sounded a cautious tone about the stock market. In this column, I will explain why someone who is cautious about the stock market can be bullish about NFLX stock and AMZN stock. Cuban does own four dividend stocks.
- Reuters•6 days ago
From blue lipstick to Facebook Live, home shopping networks refine their pitch
HSN, once known as the Home Shopping Network, is getting an image makeover. A U.S. television network where shoppers can buy everything from electronics to kitchen gadgets, HSN is overhauling its lineup to offer more beauty products while adding streamed video content to win over shoppers without cable TV. A division of Qurate Retail Group, the network is facing growing competition from Amazon Inc. and Evine Live Inc for consumers like 24-year old Erin Bounds, who regard buying products through TV shows a relic of the past.
- American City Business Journals•7 days ago
Olay spotlights fearless women in 'Face Anything' campaign
The ads feature women who have been called "too" something instead embracing their boldness.
- Reuters•7 days ago
Express Scripts staking out million-dollar gene therapies
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
- PR Newswire•7 days ago
CVS Health Statement on Ohio Department of Medicaid's Pass-Through Pricing Requirements
WOONSOCKET, R.I. , Aug. 14, 2018 /PRNewswire/ -- CVS Health (NYSE: CVS) is actively working with its Ohio Managed Medicaid clients to restructure its contracts to implement the Ohio Department of Medicaid's ...
- Market Realist•7 days ago
Top Gainers in the Consumer Sector Last Week
CVS Health (CVS) released its second-quarter results on August 8 before the market opened. The company’s revenues for the quarter grew 2.2% YoY (year-over-year) to $46.7 billion and beat the estimate by 0.8%. CVS Health’s earnings increased 27.1% YoY to $1.6 per share and exceeded the forecast of $1.6 per share.
- Market Realist•8 days ago
Consumer Sector Was Mediocre in the Week Ending August 10
So far, 91% of the companies in the S&P 500 have reported their third-quarter earnings. Last week was mediocre for the market. The S&P 500 Index (SPY) fell 0.25% for the week ending August 10. Last week was average for most of the sectors in the index.
- PR Newswire•8 days ago
CVS Health Survey Finds Consumers More Likely to Get Vaccinated Following Last Year's Record Breaking Flu Season
WOONSOCKET, R.I., Aug. 14, 2018 /PRNewswire/ -- Marking the start of flu vaccine availability, a new survey from CVS Health (CVS) released today found that one in five (22 percent) of consumers surveyed who didn't get a flu vaccine last year say that knowledge of last year's flu season – which had flu levels that were the highest observed since 2009 – makes them more likely to get vaccinated this year. On a similar note, among the 27 percent of parents of children under 18 whose child did not get the flu vaccine last year, 26 percent say they are more likely to get their child vaccinated this year after learning about the notably high flu levels during last year's flu season.
- Moody's•8 days ago
Rite Aid Pass-Through Trust, Series 1999-1 -- Moody's Places the CTL Rating of Rite Aid Pass-Through Trust, Series 1999-1 On Review For Possible Downgrade
The rating was placed on review for possible downgrade due to the Rite Aid Corporation ("Rite-Aid") senior unsecured rating being placed on review for possible downgrade by Moody's on August 9, 2018. Rite-Aid was placed on review for possible downgrade due to Rite-Aid's announcement that it has terminated its merger agreement with Albertsons Companies, Inc. The merger termination leaves Rite-Aid in a weaker position as it lacks the scale or the balance sheet to compete in the changing pharmacy landscape with much larger and well capitalized competitors like CVS Health and Walgreens Boots Alliance, Inc. The ratings of Credit Tenant Lease (CTL) deals are primarily based on the senior unsecured debt rating (or the corporate family rating) of the tenants leasing the real estate collateral supporting the bonds.
- Motley Fool•10 days ago
Is Rite Aid Corporation a Buy?
Another merger falls apart for Rite Aid. But could better days be ahead?
Motley Fool•11 days agoCVS Health (CVS) Q2 2018 Earnings Conference Call Transcript
CVS earnings call for the period ending June 30, 2018.
- Zacks•11 days ago
Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More
Top Research Reports with Q2 Earnings Analysis: Merck, CVS Health, CME Group & More
- CBS MoneyWatch•12 days ago
CVS nasal spray recalled due to contamination fears
CVS Health 12 Hour Sinus Relief Nasal Mist, a clear, colorless liquid, is a nasal decongestant
- Market Realist•12 days ago
Strong Q2 2018 Results Cushion CVS Health’s Falling Share Price
CVS Health’s (CVS) better-than-expected second-quarter results managed to please investors. The company’s share price soared 6% during the day on August 8 before finally settling at $68.17, 4.2% higher than the previous day’s close.
- Market Realist•12 days ago
Is Walgreens Stock an Attractive Bet?
As discussed in the previous section, six analysts have downgraded Walgreens Boots Alliance (WBA) since Amazon’s (AMZN) acquisition of PillPack in late June. As a result, Walgreens’s overall ratings have come down drastically. The company, which was rated 2.3 before the acquisition on June 28, is now ranked as a 2.7. Ratings are on a scale where one is a “strong buy,” and five is a “strong sell.”
- Moody's•12 days ago
Rite Aid Corporation -- Moody's places Rite Aid's rating on review for downgrade following termination of merger with Albertsons
Moody's Investors Service ("Moody's") today placed the ratings of Rite Aid Corporation (Rite-Aid) on review for downgrade including its Corporate Family Rating of B2 and its Probability of Default Rating of B2-PD. The review for downgrade is prompted by Rite-Aid's announcement that it has terminated its merger agreement with Albertsons Companies, Inc.
- Market Realist•12 days ago
Strong Retail Margins Boost CVS Health’s Q2 2018 Operating Profit
CVS Health (CVS) once again cruised ahead of bottom line expectations when it reported its second-quarter results yesterday morning. Its adjusted EPS rose 27.1% YoY (year-over-year) to $1.69, $0.08 more than the Thomson Reuters I/B/E/S estimate. This was the tenth consecutive earnings beat for the company.
- TheStreet.com•12 days ago
Rite Aid's Rotten Week: How Will It Now Compete Against Walgreens, CVS?
Rite Aid had a horrid week. The stock has been pummeled by a spate of bad news, raising questions about how Rite Aid will continue to stack up against its competitors on pricing, footprint and innovation edge. The slide thus far was punctuated by a collapse of a merger agreement with Albertsons Cos. grocery chain, sinking the shares over 9% on Thursday to $1.58 per share.
- Market Realist•12 days ago
Strength in Retail Sales Drives CVS Health’s Q2 2018 Top Line
CVS Health (CVS) posted better-than-expected quarterly sales when it reported its second-quarter results on August 8. Its top line improved 2.2% YoY (year-over-year) to $46.7 billion.
